Image For Activity Cover
GRGUH2EM2302 - CME/CMLE - HER2 Breast Cancer Tweetorial 4: HER2 equivocal and HER2-low
Course Description

Course Description

HER2 Breast Cancer Tweetorial 4: HER2 equivocal and HER2-low
 
This activity is designed to help pathologists, laboratory professionals, and other members of the cancer care team gain an understanding of the clinical implications around HER2-low breast cancer and HER2 testing guidelines. This Tweetorial will cover the following topics: the concept of HER2 “equivocal” and clinical implications around HER2-low breast cancer. 
 
The activity offers 0.5 CME/CMLE credit.
 
Provided by the American Society for Clinical Pathology in partnership with Q Synthesis LLC.
 
Target Audience
This activity has been designed to meet the educational needs of pathologists, laboratory professionals, and other members of the cancer care team.   
 
Activity Agenda

  • Background
  • HER2 equivocal 
  • Limitations of IHC
  • HER-low breast cancer
  • Wrap-up

Faculty/Authors

Joseph Kim, MD, MPH, MBA
President, Q Synthesis LLC   

Physician's Competency: Patient Care, Medical Knowledge, Practice-Based Learning, and Improvement 

CME/CMLE Credit: 0.5
Estimated Completion Time: 0.5 hour
Format: Online educational activity

Credit Designation Statement

The American Society for Clinical Pathology (ASCP) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education (CME) for physicians.

The ASCP designates this enduring internet activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

ASCP designates this enduring internet activity for a maximum of 0.5 CMLE credit.  This activity meets CMP and state re-licensure requirements for laboratory personnel.

For questions regarding CME credit, please contact ASCP Customer Service at 1-800-267-2727, during normal business hours: Monday through Friday, 8 a.m. to 6 p.m. Eastern Time


Method of Participation
To complete the activity and receive credit, the participant must complete the online activity. CME certificates will be provided online.
 
Commercial Support
Funded by independent educational grants from AstraZeneca Pharmaceuticals and Daiichi Sankyo, Inc.
Provided by the American Society for Clinical Pathology in partnership with Q-Synthesis, LLC   

Instructions

To claim CME/CMLE credit for the exercise, do the following:

  1. Review the Technical Considerations.
  2. Click Go to Content and click the first module of the course.
  3. Complete the Demographic Survey.
  4. Review the Tweetorial Instructions
  5. Review the Educational Activity.
  6. Submit the course Evaluation.
  7. Enter the maximum number of credits offered and click Claim CME/CMLE to register credit.

Faculty Disclosures  

Technical Considerations 

Release Dates:  1/31/2023     
Review Date:
Expiration Date:  1/31/2026   




Course Objectives

Upon completion of this activity, you will be able to:

  • Appropriately conduct IHC and ISH testing, classification, and reporting in routine and complex breast cancer cases across the HER2 spectrum in accordance with guidelines

  • Describe the science and emerging evidence around the diagnosis, testing, and treatment of patients with HER2-low breast cancer

  • Update laboratory processes and procedures

  • Outline ways to improve communication and coordination among pathologists, oncologists, and other members of the cancer care team when discussing HER2 test results in patients with breast cancer.

 



 


 

Summary
Availability: On-Demand
Credit Offered:
0.5 CME/CMLE Credit
Contains: 3 Courses
Powered By